Vitamin D levels in Swiss breast cancer survivors.
Swiss Med Wkly. 2018 Jan 29;148:w14576. doi: 10.4414/smw.2018.14576. eCollection 2018 Jan 29.
Baumann M1, Dani SU2, Dietrich D3, Hochstrasser A4, Klingbiel D3, Mark MT5, Riesen WF1, Ruhstaller T6, Templeton AJ7, Thürlimann B6.
- Vitamin D after breast cancer diagnosis
- Vitamin D and breast cancer radiation
- Vitamin D Might Be Able to Slash Your Breast Cancer Risk by 90 Percent - Baggerly, Mercola: May 2013
Far better to have high vitamin D and skip breast cancer than increasing Vitamin D so as to survive breast cancer/therapy
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- More survive Breast Cancer if more vitamin D – 2X fewer deaths with just 30 ng -meta-analysis March 2014
- Not enough women willing to stop taking vitamin D to permit breast cancer clinical trial – June 2012
- Following breast cancer 100,000 IU Vitamin D doses helped a lot (standard of care 400 IU daily did not) – RCT July 2016
- Evidence that Vitamin D prevents Cancer – Grant Feb 2018
Overview Breast Cancer and Vitamin D contains the following summary and sections
- 16+ meta-analyses of Vitamin D and Breast Cancer
example: 2X reduction of deaths from Breast Cancer if have enough Vitamin D.
- Appears that having lots of Vitamin D will reduce by 3 X the chance of Breast Cancer
wonder just how much more proof is needed
- Breast Cancer 4X more likely if have poor genes
- Cancer - Breast category listing has
176 items along with related searches
Vitamin D Responses - not their data
Note - some daily dosing studies have found that vitamin D levels do plateau for 25-50 weeks
Cholecalciferol (vitamin D3) is widely supplemented in breast cancer survivors because of the role of vitamin D in multiple health outcomes.
We conducted an observational study in 332 women in Eastern Switzerland with early, i.e., nonmetastatic breast cancer. Tumour-, patient-related and sociodemographic variables were recorded. Cholecalciferol intake and serum 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) levels were measured at the first visit (baseline) and during a follow-up visit in a median of 210 days (range 87-857) after the first visit. Patients presenting 25(OH)D deficiency were advised to take cholecalciferol supplementation.
At baseline, 60 (18%) patients had 25(OH)D deficiency (≤50 nmol/l, ≤20 ng/l), and 70 (21%) had insufficiency (50-74 nmol/l, 20-29 ng/l). Out of 121 patients with ongoing cholecalciferol supplementation at baseline, 25(OH)D deficiency and insufficiency was observed in 9 (7%) and 16 (13%) patients, respectively, whereas out of 52 patients with no supplementation, 15 (29%) had deficiency and 19 (37%) had insufficiency. Only 85 (26%) patients had optimal 25(OH)D levels (75-100 nmol/l, 30-40 ng/l) at baseline. Seasonal variation was significant for 25(OH)D (p = 0.042) and 1,25(OH)2D (p = 0.001) levels. Living in a rural area was associated with a higher median 25(OH)D concentration as compared with living in an urban area (87 nmol/l, range 16-216 vs 72 nmol/l, range 17-162; p = 0.001). Regular sporting activity was positively associated with 25(OH)D (p = 0.045). Body mass index was inversely related to both 25(OH)D and 1,25(OH)2D (Spearman's rho = -0.24, p <0.001; rho = -0.23, p <0.001, respectively). The levels of 25(OH)D and 1,25(OH)2D were correlated (rho = 0.21, p <0.001). Age and bone mineral density had no significant correlation with the levels of 25(OH)D. Follow-up 25(OH)D was available for 230 patients, 44 (19%) of whom had 25(OH)D deficiency and 47 (21%) had insufficiency; 25 (41.6%) initially 25(OH)D-deficient patients attained sufficient 25(OH)D levels, whereas 33 (16.5%) patients with sufficient baseline 25(OH)D levels became deficient. Only 67 (30%) patients presented optimal 25(OH)D at the follow-up.
A remarkable fraction of the patients had serum 25(OH)D below (40%) or above (30%) optimal levels, and only around 30% of patients had optimal levels. Levels of 25(OH)D and 1,25(OH)2D increased on cholecalciferol supplementation, but the usual supplementation regimens were not adequate to bring 25(OH)D to the optimal range for a large proportion of patients.
TRIAL REGISTRATION NUMBER: EKSG 08/082/2B.
PMID: 29376548 DOI: 10.4414/smw.2018.14576
100 visitors, last modified 30 Jan, 2018, URL: